基因组风险评分对系统性硬化症易感性的影响
本研究基于迄今最大规模系统性硬化症(SSc)全基因组关联研究(GWAS)的等位基因效应,在独立队列(400例SSc患者和571例对照)中构建并验证基因组风险评分(GRS)。最佳SSc GRS包含33个SNP,区分SSc与对照的AUC为0.673,联合年龄和免疫细胞计数后AUC提升至0.787,且能区分SSc与其他免疫介导炎症性疾病。
要点
- 33个SNP构成的SSc GRS区分SSc与对照的AUC为0.673。
- GRS联合年龄和免疫细胞计数后模型AUC提升至0.787。
- 血清学亚型GRS区分ACA+与ATA+患者的AUC为0.693。
核心结论
- GRS在SSc中成功实施,可区分SSc与对照或其他免疫介导炎症性疾病,支持SSc早期和鉴别诊断的潜力。
主要发现
- 最佳拟合SSc GRS包含33个单核苷酸多态性(SNP),区分SSc患者与对照的受试者工作特征曲线下面积(AUC)为0.673。
- GRS可区分SSc与其他免疫介导炎症性疾病,如类风湿关节炎和干燥综合征。
- GRS联合年龄和免疫细胞计数显著提高模型性能,AUC达0.787。
- SSc GRS不能区分ATA+与ACA+患者(AUC<0.5),而基于ACA+与ATA+患者比较的等位基因效应构建的血清学亚型GRS达到AUC=0.693。
临床怎么用
- GRS可能作为辅助工具用于SSc的早期识别和与其他免疫介导炎症性疾病的鉴别诊断。
- 联合年龄和免疫细胞计数可提升GRS模型的判别性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Genomic Risk Scores (GRS) successfully demonstrated the ability of genetics to identify those individuals at high risk for complex traits including immune-mediated inflammatory diseases (IMIDs). We aimed to test the performance of GRS in the prediction of risk for systemic sclerosis (SSc) for the first time. METHODS: Allelic effects were obtained from the largest SSc Genome-Wide Association Study (GWAS) to date (9 095 SSc and 17 584 healthy controls with European ancestry). The best-fitting GRS was identified under the additive model in an independent cohort that comprised 400 patients with SSc and 571 controls. Additionally, GRS for clinical subtypes (limited cutaneous SSc and diffuse cutaneous SSc) and serological subtypes (anti-topoisomerase positive (ATA+) and anti-centromere positive (ACA+)) were generated. We combined the estimated GRS with demographic and immunological parameters in a multivariate generalised linear model. RESULTS: The best-fitting SSc GRS included 33 single nucleotide polymorphisms (SNPs) and discriminated between patients with SSc and controls (area under the receiver operating characteristic (ROC) curve (AUC)=0.673). Moreover, the GRS differentiated between SSc and other IMIDs, such as rheumatoid arthritis and Sjögren's syndrome. Finally, the combination of GRS with age and immune cell counts significantly increased the performance of the model (AUC=0.787). While the SSc GRS was not able to discriminate between ATA+ and ACA+ patients (AUC<0.5), the serological subtype GRS, which was based on the allelic effects observed for the comparison between ACA+ and ATA+ patients, reached an AUC=0.693. CONCLUSIONS: GRS was successfully implemented in SSc. The model discriminated between patients with SSc and controls or other IMIDs, confirming the potential of GRS to support early and differential diagnosis for SSc.
引用
- Bossini-Castillo L, Villanueva-Martin G, Kerick M, et al. Genomic Risk Score impact on susceptibility to systemic sclerosis. Ann Rheum Dis. 2020. PMID: 33004331. doi:10.1136/annrheumdis-2020-218558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。